ABVC Live signaler | Maksimer profitt med Getagraph.com

KJøP 116580 min ago

@ $1.300

Utstedt: 8 feb 2024 @ 19:07

Avkastning: 5.77%

Forrige signal: feb 7 - 15:30

Forrige signal: Selg

Avkastning: -7.80 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 19:07):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
Dagens volum	1.53M
Gjennomsnittsvolum	1.09M
Markedsverdi	14.52M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00700 (0.51%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

Volum Korrelasjon

Lang: -0.20 (neutral)

Kort: -0.33 (neutral)

Signal:(43.212) Neutral

AMERICAN BRIVISION Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AMERICAN BRIVISION Korrelasjon - Valuta/Råvare

-0.78
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

0.76
( moderate )

AMERICAN BRIVISION Økonomi

Annual	2023
Omsetning:	$152 430
Bruttogevinst:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
Omsetning:	$152 430
Bruttogevinst:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
Omsetning:	$969 783
Bruttogevinst:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
Omsetning:	$355 797
Bruttogevinst:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.